

**Administration**

UCSF Box 0296  
500 Parnassus Avenue, MUE5  
San Francisco, CA 94143  
tel: 415-353-2733  
fax: 415-353-2765  
[www.ucsfhealth.org/possible](http://www.ucsfhealth.org/possible)

September 22, 2017

The Honorable Greg Walden  
Chairman  
Committee on Energy and Commerce  
U.S. House of Representatives  
Washington, DC 20515

The Honorable Frank Pallone  
Ranking Member  
Committee on Energy and Commerce  
U.S. House of Representatives  
Washington, DC 20515

The Honorable Tim Murphy  
Chairman  
Subcommittee on Oversight and Investigation  
U.S. House of Representatives  
Washington, DC 20515

The Honorable Diana Degette  
Ranking Member  
Subcommittee on Oversight and Investigation  
U.S. House of Representatives  
Washington, DC 20515

**Re: Committee on Energy and Commerce request for information about UC San Francisco (UCSF) Medical Center's participation in the 340B Drug Pricing Program**

Dear Chairman Walden, Ranking Member Pallone, Chairman Murphy and Ranking Member Degette:

This letter is in response to your recent inquiry into UC San Francisco (UCSF) Medical Center's participation in the critically important 340B Drug-Pricing Program administered by the Health Resources and Service Administration (HRSA). We welcome the opportunity to begin a dialogue with the Energy and Commerce Committee about how we utilize this program to maximize our ability to treat low-income and underserved patients that entrust us with their care.

We understand that the Committee is eager to begin their investigation into the 340B Drug Pricing Program, and it is relying on institutions' prompt response so the Committee can initiate its work. At UCSF, our team is working diligently to

thoroughly and accurately compile the 340B data and analysis requested. However, we are facing technical and logistical hurdles that include accessing data prior to implementation of our electronic medical record, as well as reconciling and reformatting fiscal and calendar year-based data. This will delay our full response beyond September 22, as we have discussed with Committee staff.

While it would be our preference to present a complete response to the Committee's inquiry once our data and analysis is completed, we are now submitting our response to question 5 of your letter dated September 8, 2017. We intend to submit the balance by October 6. We would respectfully ask to brief you the week of October 16, after our 340B team has met deadlines for competing inquiries on our 340B program that we simultaneously received on September 11, 2017 from HRSA (due October 10) and the GAO (due October 13).

UCSF appreciates the opportunity to educate you on our 340B Drug Pricing Program activities. If you have any questions about our submission, which follows this cover letter, please do not hesitate to contact Natalie Alpert, Director, Federal Government Relations (202.974.6315/[natalie.alpert@ucsf.edu](mailto:natalie.alpert@ucsf.edu)) or Ann Sparkman, UCSF Chief Medical Center Counsel (415.476.3186/[ann.sparkman@ucsf.edu](mailto:ann.sparkman@ucsf.edu)).

Respectfully,

A handwritten signature in black ink, reading "Mark R. Laret". The signature is fluid and cursive, with the first name "Mark" and last name "Laret" clearly legible.

Mark R. Laret  
President and CEO  
UCSF Health

**Administration**

UCSF Box 0296  
500 Parnassus Avenue, MUE5  
San Francisco, CA 94143

tel: 415-353-2733

fax: 415-353-2765

[www.ucsfhealth.org/possible](http://www.ucsfhealth.org/possible)

- 5. How many child-sites does your organization have registered to participate in the 340B Drug Pricing Program? Please provide a list of all child-sites, including the location of the child-site and the date it began participating in the program.**

We have 333 child-sites registered to participate in the 340B Drug Pricing Program.

By way of context, all of UCSF's child sites are located at our three hospital sites and provider-based clinics on UCSF Medical Center's license, located at Parnassus, Mount Zion, and Mission Bay, serving patients throughout the Greater Bay Area, Central Valley, and Northern California.

These sites include licensed specialty clinics that treat asthma, diabetes, HIV, hepatitis C and pediatric cancer patients, among others, as well as primary care clinics that primarily treat vulnerable and underserved patients.